Medico Remedies Ltd

Medico Remedies, a microcap in the Pharmaceuticals & Drugs sector, has faced a challenging second quarter in FY24, with declines in key financial metrics including operating cash flow and net sales. The company has underperformed the broader market, raising concerns about its profitability and management confidence.

Medico Remedies, a microcap pharmaceutical company, has recently experienced a change in evaluation reflecting its market position. In Q2 FY24-25, the company reported a ROCE of 14.77% and a decline in net sales by 7.11%. Operational performance pressures are evident, with a significant drop in PBDIT and negative annual returns.

Medico Remedies, a microcap pharmaceutical company, has recently experienced a change in evaluation amid a challenging financial environment. Key metrics reveal management efficiency issues, declining net sales, and low operating cash flow, while the company has underperformed the broader market over the past year.

Medico Remedies, a microcap pharmaceutical company, has reported a negative performance in the second quarter of fiscal year 2024-2025. The company's score has fallen from 4 to -6, with a decrease in operating cash flow and net sales. MarketsMOJO has given a 'Sell' call for the company's stock based on these results.

Medico Remedies, a microcap pharmaceutical company, reported a flat performance in the quarter ending March 2024, with a score of 4 out of 10. However, the company's Profit After Tax and Net Sales have shown significant growth year on year. On the other hand, the company's Earnings per Share have declined, indicating lower profitability. Investors should carefully evaluate these factors before investing.

Medico Remedies, a microcap pharmaceutical company, has been struggling in the market, with its stock hitting a 52-week low on June 5th, 2024. The stock is currently trading at Rs.35, -6.09% lower than the sector average, and has fallen by -5.89% in the last two days. The company's overall performance has been -59.02% in the past year, indicating challenges in its operations. According to MarketsMOJO, the stock call for Medico Remedies is 'Sell', suggesting caution for investors. The pharmaceutical industry has been performing well, but Medico Remedies has not been able to capitalize on this growth. It is important for investors to carefully analyze the company's performance before making any investment decisions.

Medico Remedies, a microcap pharmaceutical company, has hit a 52-week low on May 28, 2024, with a current stock price of Rs.36.15. Despite outperforming the sector by 0.73%, the stock is still trading lower than its moving averages, indicating a downward trend. In the past year, the company has seen a decline of -59.47%, highlighting the challenges it faces in the market.

Medico Remedies, a microcap pharmaceutical company, has experienced a decline in its stock price, reaching a 52-week low on May 27, 2024. According to MarketsMOJO, the stock has been given a Sell call and is currently trading at Rs 36.45, underperforming the sector by -2.67%. Despite this, the company remains a significant player in the pharmaceutical industry.

Medico Remedies, a microcap pharmaceutical company, has hit a 52 week low on May 15, 2024 and has been underperforming in the market with a 'Sell' call by MarketsMOJO. The stock has seen a decline of -12.57% in returns in the past three days and is trading below its moving averages. Compared to the Sensex, Medico Remedies has shown a decline of -56.14% in the past year, highlighting its underperformance in the pharmaceutical industry. This article presents factual information and does not provide any recommendations or predictions about the company's future potential.

Medico Remedies, a microcap pharmaceutical company, has hit a 52-week low in its stock price on May 14, 2024, according to MarketsMOJO. The stock has fallen to Rs.38.86, underperforming the sector by -1.66%. It has also been trading below its moving averages, indicating a downward trend. Compared to the Sensex, Medico Remedies has seen a decline of -52.93% in the past year, potentially facing challenges in the current market conditions.

Medico Remedies, a microcap pharmaceutical company, has hit a 52-week low on May 13, 2024. MarketsMOJO has given the stock a Sell rating. The stock's price summary shows a new low of Rs. 40.37, underperforming the sector by -5.23%. It is currently trading below its moving averages and has had a negative performance compared to the Sensex. This may present an opportunity for potential investors to buy at a lower price.

Medico Remedies, a microcap pharmaceutical company, has reported a positive financial performance in the quarter ending March 2024. With a 47.62% increase in net sales and a growth of 64.57% in PBT, the company has shown a strong sales trend. Additionally, its highest levels of PBDIT, PBT, PAT, and EPS in the last five quarters indicate a positive trend in the near term for the company's financials.

Medico Remedies, a microcap pharmaceutical company, has seen a decline in its stock price, reaching a 52-week low on May 8, 2024. The company's stock has been underperforming the sector and has shown a negative trend in the past three days. According to MarketsMOJO, the stock call for Medico Remedies is 'Sell'. Despite facing challenges in the current market conditions, the company remains focused on growth and improvement.

Medico Remedies, a microcap pharmaceutical company, has hit a 52-week low in its stock price, reaching Rs. 44.15 on May 7th, 2024. The stock has been consistently falling and is currently trading below its moving averages. Compared to the Sensex, the company's stock has had a negative 1-year performance of -48.67%.

Medico Remedies, a microcap pharmaceutical company, has been underperforming in the market with a 'Sell' call by MarketsMOJO. On May 2nd, 2024, the stock hit a 52-week low of Rs. 44.5, showing a decline of -3.08% in today's trading session. The stock has been on a downward trend, trading below its moving averages and showing a decline of -47.76% compared to the Sensex.

Medico Remedies, a microcap pharmaceutical company, has been underperforming in the market with a 'Sell' call by MarketsMOJO. On April 15, 2024, the stock hit a 52-week low and opened with a loss of -3.97%. In the past year, the company has seen a negative performance of -49.27%, significantly lower than the positive growth of 21.92% in the Sensex.

Medico Remedies, a microcap pharmaceutical company, has seen a decline in its stock price, reaching a 52-week low on March 27, 2024. The stock has been given a 'Sell' rating by MarketsMOJO and has underperformed the sector by -0.84%. It has also been trading below its moving averages, indicating a downward trend. Compared to the Sensex, the company has recorded a -42.35% decline, highlighting its struggles in the market.

Medico Remedies, a microcap pharmaceutical company, has recently experienced a decline in its stock price, reaching a 52-week low on March 26, 2024. According to MarketsMOJO, the stock has been given a Sell rating and is currently trading below its moving averages. It has also underperformed the sector and the Sensex, highlighting its negative 1-year performance.

Medico Remedies, a microcap pharmaceutical company, has seen a dip in its stock price, hitting a 52-week low on March 22, 2024. According to MarketsMOJO, the stock has been given a 'Sell' call and has underperformed the sector by -13.65%. The company's stock has been on a downward trend, trading below its moving averages. With a -36.57% return in the past year, Medico Remedies faces challenges in the competitive market and investors should carefully evaluate before investing.